巴一，主任医师，博士研究生导师。本科毕业于上海第二医科大学临床医学专业，博士毕业于日本北海道大学癌医学专业。入选教育部“新世纪人才”，人社部“国家百千万人才”等，享受国务院特殊津贴。曾获得国家自然奖、中华医学科技奖等奖励。
      院校引进人才，2023年加入院校。曾于2000年10月至2002年3月于美国 Scripps 研究所从事博士后研究。于2002年3月至2005年5月在南京医科大学附属第一临床医院生物治疗中心任副教授。于2005年5月至2022年12月在天津医科大学肿瘤医院任副教授、教授。

任卫健委肿瘤学专家组成员，参与制定诊疗规范及临床路径，为消化系统肿瘤规范化诊治的实施与推广奠定了基础。入选教育部“新世纪人才”，人社部“国家百千万人才”等，享受国务院特殊津贴。 多年来针对消化系统肿瘤开展了一系列基础与转化研究，以通讯作者在 Cell Research、 Molecular Cancer、Nature Communications、Advanced Science、 Oncogene、Theranostics、eClinicalMedicine和British Journal of Cancer等国际权威期刊发表 SCI 论文数十篇，并有多篇文章被列入临床医学领域“ESI”高被引论文；曾获得发明专利 4 项；积极进行转化研究，研发胰腺癌 血清 miRNA 早诊试剂盒，并且已获药监局批准。作为 PI 主持参与近 100 项国际和国内多中心临床研究。

1. Shi Y#*, Ba Y#*, Wang J, Xiong J, Gu K, Chen Y, Zheng Z, Wang Z, Guo W, Cheng Y, Yin X, Liu Y, Bai Y, Li E, Li Q, Zhu L, Li W, Jiang D, He J, Chen J, Sun J, Hou S. First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial. Signal Transduct Target Ther. 2025 May 7;10(1):147.

2. Liu R#, Ji Z#, Wang X#, Zhu L, Xin J, Ma L, Zhang J, Ge S, Zhang L, Yang Y, Ning T, Bai M, Duan J, Wang F, Sun Y, Li H*, Deng T*, Ba Y*, Hao J*. Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial. Nat Commun. 2025 Feb 10;16(1):1481.

3. Ji Z#, Wang X#, Xin J#, Ma L#, Zuo D, Li H, Su L, Lv X, Ge S, Zhang L, Liu Y, Zhang Y, Ding T, Deng T*, Ba Y*, Liu R*. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. J Immunother Cancer. 2024 Dec 9;12(12):e010041.

4. Zhou Z#, Zhang H#, Du J#, Yang J#, Pan W, Zhang Q, Wang H, Tang P*, Ba Y*, Zhang H*. A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC. Cell Death Dis. 2024 Sep 10;15(9):663.

5. Wang P#, Han Y#, Pan W#, Du J#, Zuo D#, Ba Y*, Zhang H*. Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer. MedComm (2020). 2024 Apr 4;5(4):e527.

6. Zhang Q#, Deng T, Zhang H, Zuo D, Zhu Q, Bai M, Liu R, Ning T, Zhang L, Yu Z*, Zhang H*, Ba Y*. Adipocyte-Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer Adv Sci (Weinh). 2022 Oct;9(28):e2203357.

7. Zhou, L#., Liu, R., Huang, D., Li, H., Ning, T., Zhang, L., Ge, S., Bai, M., Wang, X., Yang, Y., Wang, X., Chen, X., Gao, Z., Luo, L., Yang, Y., Wu, X., Deng, T., & Ba, Y*. (2021). Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial. EClinicalMedicine, 41, 101157.

8. Zhang H#, Deng T, Liu R, Ning T, Yang H, Liu D, Zhang Q, Lin D, Ge S, Bai M, Wang X, Zhang L, Li H, Yang Y, Ji Z, Wang H, Ying G*, Ba Y*.CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer.Mol Cancer. 2020 Feb 27;19(1):43. ESI

9. Zhang, H#., Deng, T., Liu, R., Bai, M., Zhou, L., Wang, X., Li, S., Wang, X., Yang, H., Li, J., Ning, T., Huang, D., Li, H., Zhang, L., Ying, G*., & Ba, Y*. (2017). Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nature communications, 8, 15016.ESI

10. Chen X#, Ba Y#, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J*, Zen K*, Zhang J*, Zhang CY*. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008 Oct;18(10):997-1006.  F1000